A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX.

摘要: Here, we wish to propose a new systematic approach cancer therapy, based on the targeting of mitochondrial metabolism, especially in stem cells (CSCs). In future, envision that anti-mitochondrial therapy would ultimately be practiced as an add-on more conventional largely for prevention tumor recurrence and metastasis. This oncology platform require panel FDA-approved therapeutics (e.g. Doxycycline) can safely used inhibit OXPHOS and/or biogenesis CSCs. addition, target mitochondria could also developed, optimize their ability eradicate Finally, this context, mitochondrial-based biomarkers (i.e. “Mito-signatures”) utilized companion diagnostics, identify high-risk patients at diagnosis, facilitating early detection treatment failure. summary, suggest clinical trials are warranted test possibly implement emerging strategy, variety human types. general approach, using antibiotics mitochondria, was effective killing CSCs originating from many different types, including DCIS, breast (ER(+) ER(-)), prostate, ovarian, lung pancreatic cancers, well melanoma glioblastoma, among others. Thus, term MITO-ONC-RX, describe The use re-purposed drugs will undoubtedly help accelerate evaluation these move directly into Phase II trials, saving considerable amounts time (10–15 y) billions financial resources.